Trials / Unknown
UnknownNCT05839106
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
A Phase I/IIa Study to Evaluate the Tolerance, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1032 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
Detailed description
PM1032 is a Bispecific Antibody Targeting CLDN18.2 and 4-1BB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM1032 injection | Subjects will receive PM1032 by intravenous administration. |
Timeline
- Start date
- 2022-07-08
- Primary completion
- 2025-04-10
- Completion
- 2025-12-31
- First posted
- 2023-05-03
- Last updated
- 2023-05-06
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05839106. Inclusion in this directory is not an endorsement.